课题基金 / 基金详情

GENERAL SYNTHETIC APPROACH TOWARDS THE ANGUCYCLINES

GENERAL SYNTHETIC APPROACH TOWARDS THE ANGUCYCLINES
安古环素的一般合成方法
批准号:
2429351
负责人:
Theodore M Kamenecka
金额:
$2.37万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-06-01 至

项目摘要

项目成果

Theodore M Kamenecka的其他基金

相似基金

相关文献

中文摘要
翻译
安古环素的对映体和立体选择性合成 提出了“阿奎阿霉素型”抗生素的合成方法。 苷元阿奎阿霉素。一种关键四环中间体的制备 允许对此家族的所有成员采取灵活的方法,通过 选择性C-和O-糖基化反应。一种温和的酸催化 环化反应构建了四环苯并[a]蒽核。 舒尔茨白桦树后的对映体纯形式 还原/烷基化序列。大多数角线显示出宽阔的排列 生物活性,包括抗肿瘤、抗细菌和抗病毒 活性,以及作为酶抑制剂和血液的抑制剂 血小板聚集。尽管这个家族中有近三十种抗生素 共享相同的苷元水杨霉素,至今还没有合成过 据报道。
英文摘要
An enantioselective and stereoselective synthesis of the angucycline antibiotics of the "aquayamycin-type" is proposed, including synthesis of the aglycone aquayamycin. Preparation of a key tetracyclic intermediate allows for a flexible approach to all members of this family through selective C- and O-glycosylation reactions. A mild acid catalyzed cyclization constructs the tetracyclic benz[a]anthracene core in enantiomerically pure form following a Schultz-type Birch reduction/alkylation sequence. Most of the angucylines show a wide array of biological activity, including antitumor, antibacterial and antiviral activity, as well as being enzyme inhibitors and inhibitors of blood platelet aggregation. Although nearly thirty antibiotics in this family share the same aglycone aquayamycin, to date, no synthesis has been reported.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
  • 批准号:
    10355649
  • 项目类别:
  • 资助金额:
    $18.54万
  • 财政年份:
    2021
  • 负责人:
    Theodore M Kamenecka
  • 依托单位:
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
  • 批准号:
    10595848
  • 项目类别:
  • 资助金额:
    $22.94万
  • 财政年份:
    2021
  • 负责人:
    Theodore M Kamenecka
  • 依托单位:
Drug Discovery for First-In-Class Myosin 10 Inhibitors as a Novel Target for Glioblastoma
  • 批准号:
    10704368
  • 项目类别:
  • 资助金额:
    $49.8万
  • 财政年份:
    2021
  • 负责人:
    Theodore M Kamenecka
  • 依托单位:
Development of novel therapeutics for opioid dependence
海外基金